FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316149407> ?p ?o ?g. }

• W2316149407 endingPage "249" @default.
• W2316149407 startingPage "241" @default.
• W2316149407 abstract "Purpose: To define the optimal dose of paclitaxel combining cisplatin, as weekly neoadjuvant chemotherapy (NAC) for early-stage bulky squamous cell carcinoma of the uterine cervix. Methods: A prospective trial was conducted for International Federation of Gynecology and Obstetrics stages IB2 and IIA2 cervical squamous cell carcinoma patients with magnetic resonance imaging or positron emission tomography-defined lymph node negative. Weekly fixed-dose cisplatin (40 mg/m 2 ) and 4-level dose escalation of paclitaxel (50, 60, 70, 80 mg/m 2 ) for 3 courses was given and followed by radical hysterectomy and pelvic lymph node dissection (RH-PLND) 14 to 28 days later. Postoperative adjuvant therapy was tailored according to pathologic response. Results: No dose-limiting toxicity occurred. Twelve subjects were enrolled without reaching maximum tolerated dose, nor was any RH-PLND procedure delayed for >2 weeks. Pathologic response rate was 50% (complete in 2 and partial in 4). Paclitaxel dose level seemed unrelated to pathologic response. No subjects had grade ≥3 acute adverse events. Seven patients (58.3%) received postoperative radiotherapy or chemoradiation. Patients with human papillomavirus 16-negative tumor and aged 55 years and older had marginally higher risk (100%) of adjuvant radiotherapy or chemoradiation after NAC than those with human papillomavirus 16-positive or age less than 55 ( P =0.081). With a median follow-up of 45.5 months, all 12 patients remained alive without disease. Conclusions: Weekly paclitaxel and cisplatin NAC for 3 courses can be tolerated with excellent short-term outcome. With the caveat of small number of patients, this study supports future phase II trials of weekly paclitaxel and cisplatin NAC for 4 to 5 cycles." @default.
• W2316149407 created "2016-06-24" @default.
• W2316149407 creator A5013129858 @default.
• W2316149407 creator A5013393479 @default.
• W2316149407 creator A5014223462 @default.
• W2316149407 creator A5018838858 @default.
• W2316149407 creator A5041941913 @default.
• W2316149407 creator A5045238903 @default.
• W2316149407 creator A5048454014 @default.
• W2316149407 creator A5051331130 @default.
• W2316149407 creator A5054615146 @default.
• W2316149407 creator A5057973652 @default.
• W2316149407 creator A5068912777 @default.
• W2316149407 creator A5071413390 @default.
• W2316149407 creator A5084426325 @default.
• W2316149407 date "2017-06-01" @default.
• W2316149407 modified "2023-10-14" @default.
• W2316149407 title "Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer" @default.
• W2316149407 cites W1926137745 @default.
• W2316149407 cites W1939032966 @default.
• W2316149407 cites W1972513121 @default.
• W2316149407 cites W1975039606 @default.
• W2316149407 cites W1976601504 @default.
• W2316149407 cites W1985408623 @default.
• W2316149407 cites W1990828990 @default.
• W2316149407 cites W2006045810 @default.
• W2316149407 cites W2007996065 @default.
• W2316149407 cites W2011814551 @default.
• W2316149407 cites W2013896394 @default.
• W2316149407 cites W2017631882 @default.
• W2316149407 cites W2019607817 @default.
• W2316149407 cites W2031014009 @default.
• W2316149407 cites W2036195901 @default.
• W2316149407 cites W2045598378 @default.
• W2316149407 cites W2048049145 @default.
• W2316149407 cites W2055626925 @default.
• W2316149407 cites W2067895711 @default.
• W2316149407 cites W2069585374 @default.
• W2316149407 cites W2080343755 @default.
• W2316149407 cites W2087866611 @default.
• W2316149407 cites W2104522904 @default.
• W2316149407 cites W2106787323 @default.
• W2316149407 cites W2110427769 @default.
• W2316149407 cites W2115499099 @default.
• W2316149407 cites W2132550559 @default.
• W2316149407 cites W2142707751 @default.
• W2316149407 cites W2171725862 @default.
• W2316149407 cites W3203488151 @default.
• W2316149407 cites W4239819457 @default.
• W2316149407 cites W4255356077 @default.
• W2316149407 cites W4298106286 @default.
• W2316149407 cites W4323873799 @default.
• W2316149407 doi "https://doi.org/10.1097/coc.0000000000000147" @default.
• W2316149407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25350466" @default.
• W2316149407 hasPublicationYear "2017" @default.
• W2316149407 type Work @default.
• W2316149407 sameAs 2316149407 @default.
• W2316149407 citedByCount "3" @default.
• W2316149407 countsByYear W23161494072020 @default.
• W2316149407 countsByYear W23161494072021 @default.
• W2316149407 countsByYear W23161494072022 @default.
• W2316149407 crossrefType "journal-article" @default.
• W2316149407 hasAuthorship W2316149407A5013129858 @default.
• W2316149407 hasAuthorship W2316149407A5013393479 @default.
• W2316149407 hasAuthorship W2316149407A5014223462 @default.
• W2316149407 hasAuthorship W2316149407A5018838858 @default.
• W2316149407 hasAuthorship W2316149407A5041941913 @default.
• W2316149407 hasAuthorship W2316149407A5045238903 @default.
• W2316149407 hasAuthorship W2316149407A5048454014 @default.
• W2316149407 hasAuthorship W2316149407A5051331130 @default.
• W2316149407 hasAuthorship W2316149407A5054615146 @default.
• W2316149407 hasAuthorship W2316149407A5057973652 @default.
• W2316149407 hasAuthorship W2316149407A5068912777 @default.
• W2316149407 hasAuthorship W2316149407A5071413390 @default.
• W2316149407 hasAuthorship W2316149407A5084426325 @default.
• W2316149407 hasConcept C121608353 @default.
• W2316149407 hasConcept C126322002 @default.
• W2316149407 hasConcept C126894567 @default.
• W2316149407 hasConcept C141071460 @default.
• W2316149407 hasConcept C143998085 @default.
• W2316149407 hasConcept C146357865 @default.
• W2316149407 hasConcept C151730666 @default.
• W2316149407 hasConcept C2776694085 @default.
• W2316149407 hasConcept C2777292972 @default.
• W2316149407 hasConcept C2777416452 @default.
• W2316149407 hasConcept C2777740455 @default.
• W2316149407 hasConcept C2778220009 @default.
• W2316149407 hasConcept C2778239845 @default.
• W2316149407 hasConcept C2780849966 @default.
• W2316149407 hasConcept C509974204 @default.
• W2316149407 hasConcept C71924100 @default.
• W2316149407 hasConcept C86803240 @default.
• W2316149407 hasConceptScore W2316149407C121608353 @default.
• W2316149407 hasConceptScore W2316149407C126322002 @default.
• W2316149407 hasConceptScore W2316149407C126894567 @default.
• W2316149407 hasConceptScore W2316149407C141071460 @default.
• W2316149407 hasConceptScore W2316149407C143998085 @default.
• W2316149407 hasConceptScore W2316149407C146357865 @default.

• next